Fiziksel Tıp, Rehabilitasyon ve Romatoloji Polikliniklerinde Pregabalin ve Gabapentin Reçete Edilen Hastaların Retrospektif Analizi

Öz

Amaç: Bu çalışmada, gabapentinoidlerin (gabapentin ve pregabalin) kas-iskelet sistemini tutan hastalıklarda ağrı yönetimindeki kullanımını incelemek, hastaların demografik özelliklerini, komorbiditelerini ve bu ilaçların reçete edilme nedenlerini değerlendirmek amaçlanmıştır. Yöntem: Ocak 2023 ile Temmuz 2024 tarihleri arasında Erciyes Üniversitesi Tıp Fakültesi-Fiziksel Tıp ve Rehabilitasyon ile Romatoloji polikliniklerine başvuran ve gabapentinoid tedavisi alan 18 yaş üzeri 615 hasta retrospektif olarak incelendi. Hastaların demografik özellikleri, komorbiditeleri, laboratuvar değerleri [C-reaktif protein (CRP), eritrosit sedimantasyon hızı (ESH), kan üre azotu (BUN), tahmini glomerüler filtrasyon hızı (eGFR), kreatinin], gabapentinoid ilaçların dozları ve reçete edilme nedenleri hasta kayıt sisteminden elde edildi. Bulgular: Çalışmaya dahil edilen hastaların ortalama yaşı 59.8±12,6 yıl olup, %78.2’si kadın hastalardan oluşmaktaydı. Tüm hastalarda en sık rastlanan komorbiditeler sırasıyla hipertansiyon (%51.3), romatolojik hastalıklar (%36.5) ve diyabetes mellitus (%30.3) olarak tespit edildi. En sık görülen romatolojik hastalıklar romatoid artrit (%40.6) ve spondiloartritler (%39.3) idi. Pregabalin grubunda romatolojik hastalık görülme oranı (%60.5), gabapentin grubuna (%32.8) kıyasla istatistiksel olarak anlamlı derecede daha yüksek bulundu (p <0.001). Gabapentin en sık kronik ağrı (%68.1), pregabalin ise fibromiyalji (%55.6) için reçete edilmiştir. Sonuç: Bu çalışmada, kas-iskelet sistemi hastalıklarında gabapentinoidlerin en sık kronik ağrı, nöropatik ağrı ve fibromiyalji tedavisinde reçetelendiği görüldü. Pregabalin, romatolojik komorbiditesi ve fibromiyaljisi olan hastalarda daha sık tercih edilirken, gabapentin ileri yaşlı ve kardiyovasküler risk faktörleri bulunan hastalarda daha yaygın kullanıldı. Bulgularımız, gabapentinoid reçeteleme alışkanlıklarının hastaların eşlik eden hastalıkları ve klinik özelliklerine göre değiştiğini ortaya koymaktadır.

Anahtar Kelimeler

• Pregabalin
• gabapentin
• ağrı

Retrospective Analysis of Patients Prescribed Pregabalin and Gabapentin in Physical Medicine, Rehabilitation, and Rheumatology Outpatient Clinics

Öz

Purpose: This study aims to investigate the use of gabapentinoids (gabapentin and pregabalin) in the management of pain in musculoskeletal diseases, and to evaluate the demographic characteristics, comorbidities and reasons for prescribing these drugs. Materials and Methods: Between January 2023 and July 2024, 615 patients aged ≥18 years who applied to Erciyes University Faculty of Medicine- Physical Medicine and Rehabilitation and Rheumatology outpatient clinic and received gabapentinoid treatment were retrospectively analyzed. Demographic characteristics, comorbidities, laboratory values [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), and creatinine], doses of gabapentinoid drugs, and reasons for prescription were obtained from the patient record system. Results: The mean age of the patients included in the study was 59.8±12.6 years and 78.2% were female. The most common comorbidities in all patients were hypertension (51.3%), rheumatological diseases (36.5%) and diabetes mellitus (30.3%), respectively. The most common rheumatological diseases were rheumatoid arthritis (40.6%) and spondyloarthritis (39.3%). The rate of rheumatological comorbidity was statistically significantly higher in the pregabalin group (60.5%) compared to the gabapentin group (32.8%) (p <0.001). Gabapentin was most commonly prescribed for chronic pain (68.1%) and pregabalin for fibromyalgia (55.6%). Conclusion: In this study, gabapentinoids were most frequently prescribed for the treatment of chronic pain, neuropathic pain, and fibromyalgia in patients with musculoskeletal disorders. Pregabalin was more commonly preferred in patients with rheumatological comorbidities and fibromyalgia, whereas gabapentin was more widely used in elderly patients and those with cardiovascular risk factors. Our findings reveal that gabapentinoid prescribing patterns vary according to patients’ comorbidities and clinical characteristics.

Anahtar Kelimeler

• Pregabalin
• gabapentin
• pain

Kaynakça

1. 1. International Association for the Study of Pain (IASP). IASP terminology. Washington (DC): IASP; 2021 (cited 2021 Jan 10).
2. 2. Stanos S, Brodsky M, Argoff C, Clauw DJ, D’Arcy Y, Donevan S, et al. Rethinking chronic pain in a primary care setting. Postgrad Med. 2016;128(5):502-15.
3. 3. Ablin JN, Cohen H, Neumann L, Kaplan Z, Buskila D. Coping styles in fibromyalgia: effect of co-morbid posttraumatic stress disorder. Rheumatol Int. 2008;28:649-56.
4. 4. Kosek E, Clauw D, Nijs J, Baron R, Gilron I, Harris RE, et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain. 2021;162(11):2629-34.
5. 5. Fitzcharles M-A, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098-110.
6. 6. Minhas D. Pain mechanisms for the practicing rheumatologist. Best Pract Res Clin Rheumatol. 2024;101942.
7. 7. Kidd B, Urban L. Mechanisms of inflammatory pain. Br J Anaesth. 2001;87(1):3-11.
8. 8. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267-84.

9. 9. Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med. 2002;8(8):390-6.
10. 10. Wigerblad G, Bas DB, Fernades-Cerqueira C, Krishnamurthy A, Nandakumar KS, Rogoz K, et al. Autoantibodies to citrullinated proteins may induce joint pain independent of inflammation. Ann Rheum Dis. 2016;75(4):730-8.
11. 11. Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGraize SC, et al. Glial–cytokine–neuronal interactions underlying the mechanisms of persistent pain. J Neurosci. 2007;27(22):6006-18.
12. 12. Hardie RC. TRP channels and lipids: from Drosophila to mammalian physiology. J Physiol. 2007;578(1):9-24.
13. 13. Amaya F, Wang H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J, et al. The voltage-gated sodium channel Nav1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci. 2006;26(50):12852-60.
14. 14. Hucho TB, Dina OA, Levine JD. Epac mediates a cAMP-to-PKC signaling in inflammatory pain: an isolectin B4(+) neuron-specific mechanism. J Neurosci. 2005;25(26):6119-26.
15. 15. Falasinnu T, Nguyen T, Jiang TE, Chaichian Y, Rector A, Darnall BD, et al. The problem of pain in rheumatology: clinical profiles associated with concomitant diagnoses with chronic overlapping pain conditions. ACR Open Rheumatol. 2022;4(10):890-6.
16. 16. Bingham B, Ajit SK, Blake DR, Samad TA. The molecular basis of pain and its clinical implications in rheumatology. Nat Clin Pract Rheumatol. 2009;5(1):28-37.
17. 17. Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020;14(2):104-14.
18. 18. Külekçioğlu S, Akyüz M, Çetin A. Retrospective cohort study of gabapentinoid drug use in hospitalized physical medicine and rehabilitation clinic patients. J Phys Med Rehabil Sci. 2022;25(1):1-8.
19. 19. Johansen ME, Maust DT. Update to gabapentinoid use in the United States, 2002-2021. Ann Fam Med. 2024;22(1):45-9.
20. 20. Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med. 2019;179(5):695-701.
21. 21. Ünlütürk Z. Neuropathic pain and neurology clinic: single center data in Kocaeli province tertiary care hospital. Kocaeli Med J. 2023;12(2):230-2.
22. 22. Bekircan-Kurt CE, Berin İ, Bulut O, Şengün İ, Karli N, Güneş N, et al. Neuropathic pain frequency in neurology outpatients: a multicenter study. Arch Neuropsychiatry. 2021;58(4):257-62.
23. 23. McGeeney BE. Pharmacological management of neuropathic pain in older adults: an update on peripherally and centrally acting agents. J Pain Symptom Manage. 2009;38(2 Suppl):S15-27.
24. 24. Buvanendran A, Kroin JS, Kari M, Tuman KJ. Can a single dose of 300 mg of pregabalin reach acute antihyperalgesic levels in the central nervous system? Reg Anesth Pain Med. 2010;35(6):535-8.
25. 25. Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract. 2010;11:85.
26. 26. Sreekantaswamy SA, Mollanazar N, Butler DC. Gabapentinoids for pruritus in older adults: a narrative review. Dermatol Ther (Heidelb). 2021;11:669-79.
27. 27. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661-9.
28. 28. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel α2–δ subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137-50.
29. 29. Erden Y, Kaya SS, Okçu M. Pregabalin ve gabapentin kullanım bozuklukları. J Phys Med Rehabil Sci. 2019;22(3):134-9.
30. 30. Mogil JS, Parisien M, Esfahani SJ, Diatchenko L. Sex differences in mechanisms of pain hypersensitivity. Neurosci Biobehav Rev. 2024;158:105749.
31. 31. Winslow BT, Vandal C, Dang L. Fibromyalgia: diagnosis and management. Am Fam Physician. 2023;107(2):137-44.
32. 32. Kim J-R, Kim HA. Molecular mechanisms of sex-related differences in arthritis and associated pain. Int J Mol Sci. 2020;21(21):7938.
33. 33. Presto P, Mazzitelli M, Junell R, Griffin Z, Neugebauer V. Sex differences in pain along the neuraxis. Neuropharmacology. 2022;210:109030.
34. 34. Siracusa R, Paola RD, Cuzzocrea S, Impellizzeri D. Fibromyalgia: pathogenesis, mechanisms, diagnosis and treatment options update. Int J Mol Sci. 2021;22(8):3891.
35. 35. Ji R-R, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? Pain. 2013;154 Suppl 1:S10-28.
36. 36. Athavale A, Murnion B. Gabapentinoids: a therapeutic review. Aust Prescr. 2023;46(4):80-6.
37. 37. Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645-60.
38. 38. Goins A, Patel K, Alles SR. The gabapentinoid drugs and their abuse potential. Pharmacol Ther. 2021;227:107926.
39. 39. Gu X, Chen TC, Su TL, Steinke D, Chen LC. Investigating the prescribing trajectory and geographical drug utilisation patterns of gabapentinoids in primary care in England: an ecological study. Br J Clin Pharmacol. 2021;87(10):4001-12.
40. 40. Zhao D, Baek J, Hume AL, McPhillips EA, Lapane KL. Geographic variation in the use of gabapentinoids and opioids for pain in a commercially insured adult population in the United States. J Pain Res. 2022;15:443-54